Evotec's Double Squeeze: Can a Growing Core Business Offset a Second Guidance Meltdown?

Evotec stock down 52.6% in year after second profit warning. 2026 revenue forecast cut to €570-610M with EBITDA loss. RSI 22.6 oversold but below all key moving averages.

Evotec shares closed at €3.50 on Tuesday, hovering just 9.6% above their 52-week low of €3.19 set on July 14. The stock has shed 52.6% over the past twelve months, and that slide accelerated sharply after the company issued its second major profit warning in four months. Trading volumes surged as investors scrambled to reassess whether this is a buying opportunity in deeply oversold territory or the start of a new, lower valuation regime.

The catalyst was a dramatic cut to Evotec's 2026 outlook, based on provisional and unaudited half-year figures. The Hamburg-based drug discovery and development partner now expects full-year revenue between €570 million and €610 million, with adjusted EBITDA losses ranging from €70 million to €105 million. At constant currencies, those figures are €595–635 million and a loss of €60–90 million respectively. Just three months ago, management had guided for a break-even to slightly positive adjusted result.

The first-half numbers paint a stark picture: group revenue of roughly €300.1 million and an adjusted EBITDA loss of €42.7 million. Evotec's finance chief Claire Hinshelwood attributed roughly 40% of the revenue shortfall to a shift into 2027, around 45% to delays in negotiating strategic partnerships, and the remaining 15% to weaker revenue recognition. She stressed that partnership revenue carries above-average margins, meaning the hit to earnings is disproportionately harsh compared with the top-line miss.

Yet within those numbers lies a more encouraging story. Evotec's core discovery and preclinical development (D&PD) business, excluding strategic partners, saw net sales jump about 28% in the first half, buoyed by stronger customer retention. The company's restructuring program, Horizon, is also on schedule: it aims to cut the cost base by €75 million by the end of 2027, with 20% to 30% of that targeted for 2026 alone. On the balance sheet, Evotec held roughly €465.6 million in cash at the end of June, providing a cushion for the roughly €100 million in restructuring cash outlays planned through 2028.

The bulls point to a relative strength index of 22.6, deep in oversold territory, which historically favours short-term bounces if the newsflow stabilises. But the bear case is equally punchy. This is the second time Evotec has slashed its 2026 forecast — the first was in March, when it unveiled a transformation plan promising sustainable growth. The latest warning prompted RBC analyst Charles Weston to call it "another material profit warning." Meanwhile, the company's biologics arm, Just Evotec Biologics, shrank 17% year-on-year in the second quarter to €35.4 million in revenue, and 29% in the first half to €72.3 million.

Technically, the stock is trading below all key moving averages — the 50-day at €4.79, the 100-day at €4.88, and the 200-day at €5.38 — confirming a broad and intact downtrend. Most analyst price targets still reflect the pre-warning environment, making consensus figures unreliable for now.

The most pressing question for investors is whether Evotec's liquidity is sufficient to fund its turnaround without a dilutive capital raise. The cash pile of €465.6 million looks adequate on its own, but the combination of operating losses and restructuring costs will drain it quarter by quarter. If the delayed partnerships fail to materialise or more revenue shifts to the right, the financing headroom could tighten faster than the company anticipates.

Management remains upbeat, insisting that "our pipeline is today more active than ever" and pointing to advanced talks on partnerships in kidney disease, oncology, women's health, and obesity. But the market has heard such promises before — the March transformation plan came with similarly optimistic language, and now those assumptions lie in tatters.

The next checkpoint is clear: the audited half-year report due on August 13. That document must show whether the cost program is genuinely taking hold and whether the revenue delays are truly timing-related or reflect a deeper structural shift in client demand. If the core D&PD growth can continue to offset partnership disappointments, a gradual stabilisation near current levels is plausible. But if the cash burn accelerates or the pipeline deals stall again, the stock will almost certainly test its €3.19 floor — and perhaps break through it.